Aligos Therapeutics Revenue vs. Price To Sales

ALGS Stock  USD 25.78  0.97  3.63%   
Based on Aligos Therapeutics' profitability indicators, Aligos Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess Aligos Therapeutics' ability to earn profits and add value for shareholders.
 
Total Revenue  
First Reported
2019-09-30
Previous Quarter
1.1 M
Current Value
1.3 M
Quarterly Volatility
3.2 M
 
Covid
Sales General And Administrative To Revenue is likely to gain to 3.82 in 2024, whereas Price To Sales Ratio is likely to drop 25.26 in 2024. At this time, Aligos Therapeutics' Accumulated Other Comprehensive Income is comparatively stable compared to the past year. Net Interest Income is likely to gain to about 1.3 M in 2024, whereas Operating Income is likely to drop (92.5 M) in 2024.
For Aligos Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Aligos Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Aligos Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Aligos Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Aligos Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
For more information on how to buy Aligos Stock please use our How to Invest in Aligos Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aligos Therapeutics. If investors know Aligos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aligos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.99)
Revenue Per Share
1.005
Quarterly Revenue Growth
(0.61)
Return On Assets
(0.67)
Return On Equity
(1.47)
The market value of Aligos Therapeutics is measured differently than its book value, which is the value of Aligos that is recorded on the company's balance sheet. Investors also form their own opinion of Aligos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aligos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aligos Therapeutics' market value can be influenced by many factors that don't directly affect Aligos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aligos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aligos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aligos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Aligos Therapeutics Price To Sales vs. Revenue Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Aligos Therapeutics's current stock value. Our valuation model uses many indicators to compare Aligos Therapeutics value to that of its competitors to determine the firm's financial worth.
Aligos Therapeutics is rated third in revenue category among its peers. It also is rated third in price to sales category among its peers . The ratio of Revenue to Price To Sales for Aligos Therapeutics is about  1,006,827 . At this time, Aligos Therapeutics' Total Revenue is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Aligos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Aligos Revenue vs. Competition

Aligos Therapeutics is rated third in revenue category among its peers. Market size based on revenue of Health Care industry is presently estimated at about 220.64 Million. Aligos Therapeutics holds roughly 15.53 Million in revenue claiming about 7% of equities under Health Care industry.

Aligos Price To Sales vs. Revenue

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Aligos Therapeutics

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
15.53 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Aligos Therapeutics

P/S

 = 

MV Per Share

Revenue Per Share

 = 
15.42 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Aligos Price To Sales Comparison

Aligos Therapeutics is currently under evaluation in price to sales category among its peers.

Aligos Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Aligos Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Aligos Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Aligos Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Aligos Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income545 K572.2 K
Net Interest Income1.2 M1.3 M
Interest Income1.2 MM
Operating Income-88.1 M-92.5 M
Net Loss-87.7 M-92.1 M
Income Before Tax-86.9 M-91.2 M
Total Other Income Expense Net1.2 M1.3 M
Net Loss-86.4 M-90.8 M
Net Loss-87.7 M-92.1 M
Income Tax Expense795 K834.8 K
Non Operating Income Net Other-65.5 K-68.8 K
Change To Netincome16.9 M9.7 M
Net Loss(3.52)(3.70)
Income Quality 0.90  0.62 
Net Income Per E B T 1.01  0.80 

Aligos Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Aligos Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Aligos Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Aligos Therapeutics' important profitability drivers and their relationship over time.

Use Aligos Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aligos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aligos Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Aligos Therapeutics Pair Trading

Aligos Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Aligos Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aligos Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aligos Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aligos Therapeutics to buy it.
The correlation of Aligos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aligos Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aligos Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aligos Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Aligos Therapeutics position

In addition to having Aligos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Target Risk ETFs Thematic Idea Now

Target Risk ETFs
Target Risk ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Risk ETFs theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Risk ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Aligos Stock Analysis

When running Aligos Therapeutics' price analysis, check to measure Aligos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aligos Therapeutics is operating at the current time. Most of Aligos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aligos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aligos Therapeutics' price. Additionally, you may evaluate how the addition of Aligos Therapeutics to your portfolios can decrease your overall portfolio volatility.